Journal article
Apixaban-Calibrated Anti-FXa Activity in Relation to Outcome Events and Clinical Characteristics in Patients with Atrial Fibrillation: Results from the AVERROES Trial
Abstract
Background In patients with nonvalvular atrial fibrillation (AF), apixaban is given in doses of 5 or 2.5 mg twice daily, according to clinical characteristics. The usual on-treatment range of apixaban drug levels, as determined by apixaban-calibrated anti-factor Xa (anti-Xa) activity, has previously been measured in small cohorts; however, the association between anti-Xa activity and clinical outcomes and the predictors of variability in …
Authors
Bhagirath VC; Eikelboom JW; Hirsh J; Coppens M; Ginsberg J; Vanassche T; Yuan F; Chan N; Yusuf S; Connolly SJ
Journal
TH Open, Vol. 01, No. 02, pp. e139–e145
Publisher
Thieme
Publication Date
July 2017
DOI
10.1055/s-0037-1613679
ISSN
2567-3459